Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | PREP | P48147 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | CPT1A | P50416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730616 | 0.88 | HSD11B1 (0.37) | PKMGFERDPP4DPP8DPP9 | |
| SCHEMBL32676800 | 0.87 | GRM5 (0.33) | PKMGFERDPP4DPP8DPP9 | |
| SCHEMBL30730564 | 0.79 | LMNA (0.40) | PKMGFERALDH1A1 | |
| SCHEMBL30730537 | 0.79 | LMNA (0.40) | PKMGFERALDH1A1 | |
| SCHEMBL30730635 | 0.78 | GRM5 (0.43) | ALDH1A1 | |
| SCHEMBL32677029 | 0.76 | GRM5 (0.41) | PKMGFERALDH1A1CPT1A | |
| SCHEMBL30730547 | 0.74 | PKM (0.38) | PKMCPT2CPT1A | |
| SCHEMBL30730444 | 0.73 | HSD11B1 (0.37) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL32676920 | 0.73 | LMNA (0.41) | PKMGFERALDH1A1 | |
| SCHEMBL32676615 | 0.73 | GRM5 (0.33) | DPP4DPP8DPP9DPP7PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | PKM 2873/4885GFER 2733/4885DPP4 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.